Joseph Patrick McEvoy, MD
Psychiatry & Behavioral Sciences
Translational Neuroscience
Psychiatry & Behavioral Sciences
Duke University Medical Center, Durham, NC.
Academic Articles
Selected Publications:
McEvoy, Joseph P., Matthew Byerly, Robert M. Hamer, Rosalie Dominik, Marvin S. Swartz, Robert A. Rosenheck, Neepa Ray, et al. “Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.” Jama 311, no. 19 (May 21, 2014): 1978–87. https://doi.org/10.1001/jama.2014.4310.
Jarskog, L Fredrik, Robert M. Hamer, Diane J. Catellier, Dawn D. Stewart, Lisa Lavange, Neepa Ray, Lauren H. Golden, Jeffrey A. Lieberman, T Scott Stroup, and T Scott METS Investigators. “Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.” Am J Psychiatry 170, no. 9 (September 2013): 1032–40. https://doi.org/10.1176/appi.ajp.2013.12010127.
Goff, Donald C., Joseph P. McEvoy, Leslie Citrome, Arnold W. Mech, Juan R. Bustillo, Roberto Gil, Peter Buckley, Theo C. Manschreck, Eric D. Achtyes, and Eric A. Macklin. “High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study.” J Clin Psychopharmacol 33, no. 4 (August 2013): 485–90. https://doi.org/10.1097/JCP.0b013e3182977308.
McEvoy, J., R. A. Baillie, H. Zhu, P. Buckley, M. S. Keshavan, H. A. Nasrallah, G. G. Dougherty, J. K. Yao, and R. Kaddurah-Daouk. “Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics.” Plos One 8, no. 7 (July 24, 2013). https://doi.org/10.1371/journal.pone.0068717.
Jarskog, L Fredrik, Zhengchao Dong, Alayar Kangarlu, Tiziano Colibazzi, Ragy R. Girgis, Lawrence S. Kegeles, Deanna M. Barch, et al. “Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.” Neuropsychopharmacology 38, no. 7 (June 2013): 1245–52. https://doi.org/10.1038/npp.2013.23.
